Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus corticosteroids in pediatric acute graft-versus-host disease
NL-OMON48950Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib and corticosteroids in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Novartis. Planned start Dec 2018; status: withdrawn.
02
Drugs
ruxolitinibcorticosteroids
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON48950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48950.